2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 18

Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 79

Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 513

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 518

Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 551

Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 690

Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 549

US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 161

Use of a Systematic Consensus Process to Inform Development of the Veterans Health Affairs Simulation Learning, Education and Research Network (SimLEARN) Musculoskeletal Clinician Course

Education Poster

9:00AM-11:00AM: Abstract Number: 370

Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 662

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 407

Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 212

Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 303

Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission

Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 665

Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 81

UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury

SLE – Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].